Dexamethasone sodium phosphate is under clinical development by Scilex Holding and currently in Phase III for Back Pain. According to GlobalData, Phase III drugs for Back Pain have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dexamethasone sodium phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dexamethasone sodium phosphate overview

Dexamethasone sodium phosphate (SEMDEXA) is under development for the treatment of Lumbosacral radicular pain (a type of chronic low back pain) and sciatica. The drug candidate is administered through epidural route. It is formulated as a gel. The drug candidate is a non-opioid steroid injectable without surfactants, preservatives or particulates.

Scilex Holding overview

Scilex Holding (Scilex) is a biopharmaceutical company that develop and commercialize non-opioid pain management solutions for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California, the US.

For a complete picture of Dexamethasone sodium phosphate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.